Finally, the neo-adjuvant treatment of HER2-positive breast cancer has shown promise in phase II studies with the combination of metformin, liposomal adriamycin, docetaxel, and trastuzumab [127], as illustrated in Table 1. Here, ERBB2 is linked to breast cancer.